GlassScriptPhysician profile
Bassel Al-Lahham
NPI 1619081577
$2,201.79
in general payments reported to CMS, 2019-2025
16 companies · $97.69 in 2025
The $97.69 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.84 · 2020: $47.34 · 2021: $178 · 2022: $422 · 2023: $770 · 2024: $595 · 2025: $97.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,463.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $323.26 | 2021-2025 | General - Hemostasis |
| Abbvie INC. | $232.61 | 2023 | Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $224.29 | 2022-2023 | Zeposia |
| Janssen Biotech, INC. | $174.61 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $144.98 | 2024 | Iqirvo |
| Madrigal Pharmaceuticals | $144.22 | 2024 | Rezdiffra |
| Genzyme Corporation | $143.97 | 2024 | |
| Medtronic, INC. | $138.57 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.71 | 2023-2024 | Xifaxan, Trulance |
| Enterra Medical, INC. | $129.63 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $119.32 | 2023 | |
| Intercept Pharmaceuticals, INC. | $113.37 | 2023 | Ocaliva |
| Gilead Sciences, INC. | $63.52 | 2019-2020 | |
| Endogastric Solutions, INC | $63.02 | 2022 | |
| Intuitive Surgical, INC. | $32.00 | 2023 | Da Vinci Surgical System |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $19.71 | 2023 | Airseal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassel Al-Lahham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.